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ABSTRACT
Background and aim: Increased expression of the epidermal
growth factor receptor (EGFR) in non-small cell lung cancer
(NSCLC), supporting the tumor growth by a possible
endocrine mechanism, affects patient survival negatively. We
designed a study to test EGFR expression by immunohisto-
chemistry (IHC) in resected stage I–II NSCLC and to correlate
its overexpression with survival. 
Methods: EGFR expression was evaluated in 98 consecutive
NSCLC patients after complete resection (53 squamous cell
carcinomas, 40 adenocarcinomas, 5 large cell carcinomas:
stage I, 57 (58%) and stage II, 41 (42%). IHC was used to
examine the expression of EGFR in resected lung tumor sam-
ples obtained from these patients, who had no pre- or post-
operative chemotherapy or radiotherapy. Univariate and mul-
tivariate analyses were performed for factors influencing
patient survival.
Results: EGFR was expressed in 51 (52%) of 98 NSCLC sam-
ples. More squamous tumors (61%) were EGFR-positive than
adenocarcinomas (38%) (p = 0.038). There was a statistically
significant correlation between EGFR expression and stage (p
= 0.04). No difference was found between EGFR positive and
negative tumors in the 5-year overall survival (57% vs. 73%,
p = 0.13). 
Conclusion: The level of EGFR expression in tumors was not a
successful predictor of survival in resected NSCLC. 
Keywords: Epidermal growth factor receptor, immunochem-
istry, non-small cell lung carcinoma.
RIASSUNTO 
Razionale e scopo: Un’espressione aumentata del recettore
per il fattore di crescita epidermica (EGFR) nel tumore polmo-
nare non a piccole cellule (NSCLC), che supporta un possibile
meccanismo endocrino nella crescita tumorale, ha un impatto
negativo sulla sopravvivenza del paziente. Abbiamo pianifica-
to uno studio sull’espressione del EGFR con metodica immu-
noistochimica (IHC) su NSCLC asportati in stadio I-II e per
correlarne la sovraespressione con la sopravvivenza.
Metodi: L’espressione dell’EGFR è stata valutata in 98 pazienti
consecutivi con NSCLC dopo la resezione totale (53 carcinomi
a cellule squamose, 40 adenocarcinomi, 5 carcinomi a grandi
cellule; stadio I: 57 (58%) e stadio II: 41 (42%). È stato utiliz-
zato un IHC per esaminare l’espressione del EGFR in campioni
di tumori polmonari resecati ottenuti da questi pazienti, non
sottoposti a chemo o radioterapia pre- o post-operatoria.
Sono state effettuate analisi univariate e multivariate sui fat-
tori che influenzano la sopravvivenza dei pazienti.
Risultati: L’EGFR era espresso in 51 (52%) su 98 campioni di
NSCLC. Vi era una quota maggiore di tumori squamosi (61%)
EGFR-positivi rispetto agli adenocarcinomi (38%) (p = 0,038).
Vi era una correlazione statisticamente significativa tra
espressione di EGFR e lo stadio del tumore (p = 0,04). Non è
stata riscontrata una differenza tra tumori positivi o negativi
per EGFR nella sopravvivenza complessiva a 5 anni (57% vs.
73%, p = 0,13). 
Conclusione: Il livello di espressione del EGFR nei tessuti tu-
morali non è risultato un predittore attendibile nei NSCLC re-
secati.
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INTRODUCTION
Most patients with non-small cell lung cancer
(NSCLC) who survive for a long time have tumors at
TNM stage I or II at the time of initial diagnosis.
However, the 5-year survival rates are not yet satis-
factory even in these early stage patients. For patho-
logic stages IA, IB, IIA and IIB, 5-year survival is
approximately 70%, 60%, 55%, and 40%, respec-
tively [1]. Most patients with early stage NSCLC
experience recurrence and die as a result of the dis-
ease, despite potentially curative treatment.
Surgical resection is the standard treatment for these
stages, and the efficacy of adjuvant therapy in this
patient group has not been confirmed [2]. However,
early detection of a subgroup having early stage
NSCLC with a higher risk of recurrence/metastasis
may create a basis for aggressive adjuvant therapy,
which could help to improve the survival rate in
these patients. 
Many factors considered to affect the prognosis in
patients with resected NSCLC have been and are
still being investigated. Recent developments in
cytogenetic and molecular biology have provided
new ways to analyse prognosis. Biological substag-
ing, using molecular markers, in a risk stratification
strategy has been proposed. Tumor suppressor
genes, proto-oncogenes and markers of metastatic
propensity and proliferation are some of the differ-
ent research markers [3,4]. Among them, the epi-
dermal growth factor (EGF) family plays an impor-
tant role in the formation and progression of lung
cancers [5].
The epidermal growth factor receptor (EGFR) forms
one of the best defined autocrine growth loops in
human tumors. EGFR is a 170 kd receptor tyrosine
kinase (TK) that dimerizes and phosphorylates sev-
eral tyrosine residues upon binding of several spe-
cific ligands including epidermal growth factor and
transforming growth factor alpha [6]. After epider-
mal growth factor binding, the receptor autophos-
phorylates tyrosine residues in its cytoplasmic
domain and triggers a cascade that leads to cellular
proliferation, angiogenesis, metastasis and inhibi-
tion of apoptosis [7]. EGFR has been reported to act
as a strong prognostic marker in head and neck
cancers [8], genito-urinary carcinomas [9] and
esophageal cancers [10]. In NSCLC, however, find-
ings have been more ambiguous. Some of the pre-
vious studies reported that EGFR overexpression
predicted a poor outcome [11,12]. However, more
recent studies using specimens from larger numbers
of patients suggested that EGFR expression was not
associated with poor outcome [13-15]. However,
various differences exist in these studies, such as the
use of different methods for evaluating EGFR
expression, use of different cut of values for EGFR
positivity, inclusion of cases with heterogeneous
stages, and inclusion of cases which have been
treated before. Due to these disparities the need for
more studies is obvious. The present study was per-
formed to assess the effects of the level of EGFR
expression in tumoral tissue, measured by immuno-
histochemical methods, on the survival of patients
with early stage NSCLC. 
MATERIALS AND METHODS
A total of 98 patients with NSCLC - tumors staged
as T1 or T2 and N0 or N1- M0 (stage I-II) after
pathological evaluation - who underwent success-
ful complete resection between January 1999 and
January 2007 without operative mortality (no deaths
in hospital or within the first 30 days post-surgery)
and without pre- or post-operative chemotherapy
and/or radiotherapy were included in the study. As
this was a retrospective study, institutional review
board approval was not required. The Scientific
Study Committee of our hospital reviewed and
approved the database. 
The patients (males = 89 [90%]) had a mean age of
55.6 ± 9 (36-78) years. Mediastinoscopy was per-
formed in 94 patients (96%) as part of routine pre-
thoracotomy mediastinal evaluation and no medi-
astinal metastasis was detected. In the other 4
patients, computerized tomography of the thorax or
positron emission tomography was used to elimi-
nate the risk of mediastinal lymphatic metastasis.
Systematic mediastinal lymphatic dissection was
performed during thoracotomy along with appropri-
ate lung resection. Lung resection consisted of
lobectomy in 72 patients and pneumonectomy in
26 patients (Table I). 
Resected specimens were sent to our pathology
department for histopathological and immunohisto-
chemical examination. Specimens were fixed in
10% formalin and embedded in paraffin. The
longest diameter of the tumors was measured and
one or two 4 µm thick sections were obtained for
each centimeter of tumor from the areas containing
viable tumor tissue at maximum ratio with no (or
minimum) hemorrhage or necrosis. Several sections
were subjected to routine hematoxylin–eosin stain-
ing, while the others were kept for immunohisto-
chemical staining. Tumors were staged after thora-
cotomy (pTNM) according to the International
System for Staging Lung Cancer developed by the
American Joint Committee for Cancer (AJCC) in
1997 [1]. Histopathological tumor types were deter-
mined according to the classification of the World
Health Organization [16]. Histopathological tumor
types and differentiations, T and N stages, and
tumor sizes are shown in Table I. 
Immunohistochemical staining (IHS)
Among the prepared sections, one section contain-
ing maximum tumor tissue and minimum or no
necrosis and hemorrhage was chosen for each
patient. Sections were placed on adhesive (poly-L-
lysine)-coated slides, deparaffinized through a grad-
uated xylene and alcohol series, and then rehydrat-
ed in distilled water. Antigen retrieval was per-
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formed by adding citrate buffer and heating in a
microwave oven. Sections were incubated in a 3%
hydrogen peroxide solution to remove endogen per-
oxidase activity and washed with a phosphate-
buffered saline (PBS) solution. The UV blocking pro-
cedure was carried out to remove nonspecific
immunoreactivity. IHS for EGFR to highlight EGFR
expression was performed using a sensitive strepta-
vidin-biotinylated peroxidase complex system. All
procedures were performed in accordance with the
antibody manufacturer’s protocols. Sections were
incubated with anti-EGFR mAb (Monoclonal
Mouse Anti-Human, Cat. No. M7239) as primary
antibodies olarak (Dako North America, Inc, 6392
Via Real Carpinteria, CA 93013 USA). Then, anti-
gen–antibody complexes were visualized using a
biotin-labeled secondary antibody and streptavidin.
After this procedure, amino ethyl-carbazole chro-
mogen (ScyTek®) was applied to the sections. Then
contrast staining was performed using Mayer’s
hematoxylin, and sections were covered with a
water-based mounting medium (Aqueous-Mount,
ScyTec®).
Evaluation of the immunohistochemical staining
Two pathologists (NB and NF) who were unaware
TABLE I: PROGNOSTIC FACTORS REVEALED BY UNIVARIATE AND MULTIVARIATE ANALYSES IN PATIENTS WITH COMPLETELY
RESECTED NON-SMALL CELL CARCINOMA OF THE LUNG (N = 98).   
Number of patients 5-year survival Univariate analysis Multivariate




Female 9 (10%) 44%
Male 89 (90%) 68%
Tumor size 0.48
< 20 mm 10 (10%) 81%
21-30 mm 13 (13%) 66%
31-50 mm 46 (47%) 55%
> 50 mm 29 (30%) 53%
Tumor localization 0.98
Left 33 (34%) 65%
R ight 65 (66%) 67%
T classification 0.49
T1 23 (23%) 76%
T2 76 (77%) 63%
N classification 0.018 0.01
N0 57(58%) 76% 2.3 (1.15-4.8)
N1 41(42%) 49%
Histology 0.013 0.03
Squamous cell 53 (54%) 79% 2.2 (1.05-4.6)
Adenocarcinoma 40 (40%) 49%
Others 5 (6%) 60%
Tumor differentiation 0.81
Poor  45 (46%) 62%
Moderate 39 (40%) 67%
Well  14 (14%) 69%
Surgical procedure 0.80
Lobectomy 72 (73%) 69%
Pneumonectomy 26 (27%) 66%
Perineural invasion 0.4
Positive 25 (26%) 63%
Negative 73 (74%) 71%
Blood vessel invasion 0.068 0.75
Positive 55 (56%) 57% 1.14 (0.4-2.7)
Negative 43 (44%) 75%
Lymphatic vessel invasion 0.82
Positive 79 (80%) 66%
Negative 19 (20%) 62%
EGFR expression 0.13 0.23
Positive 51 (52%) 57% 1.6 (0.7-3.6)






























1 of clinical data independently evaluated EGFR
staining. EGFR assessment was based on cytoplas-
mic staining intensity and was scored as 0 (nega-
tive, < 5% of cells stained), 1+ (weak, 5-20% of
cells stained), 2+ (moderate, 20-50% of cells
stained), and 3+ (strong, > 50% of cells stained).
Only tumors exhibiting 2+ or 3+ staining were con-
sidered positive for EGFR expression [13].
Patients were routinely followed up with regard to
survival or recurrence at 6-month intervals.
Additionally, patients were called by phone and
some new information was received during the
preparation of the manuscript. The mean follow up
period was 46.5 ± 21.5 months (2–94 months). The
survival period was calculated using the day of lung
resection as the first day and the day of death or the
last follow up as the last day. 
Statistical analysis
Cases were evaluated for demographic, surgical
and pathological variables, and the distributions of
these variables were compared using the χ2 test or
Fisher’s exact test. Correlations were determined
using the Spearman rank correlation test. Patient
survival was analyzed by the Kaplan–Meier
method, using time zero as the date of thoracotomy
and death as the endpoint. Postoperative mortalities
were excluded from the survival analysis.
Prognostic factors were evaluated in the completely
resected patients. Differences in survival were
determined by log-rank test at univariate analysis
and prognostic factors with p-values less than 0.15
were included in a multivariate analysis using the
Cox proportional hazards regression model. Results
were considered significant at p < 0.05. 
RESULTS
The overall 5-year survival rate of the patients was
calculated as 65%. The 5-year survival rate was
76% for patients with stage I disease and 49% for
patients with stage II disease. This difference was
statistically significant (p = 0.018). The effects of
histopathological type on survival were assessed,
and the 5-year survival rate was found to be 79%
for patients with squamous cell carcinoma, 49% for
patients with adenocarcinoma, and 60% for
patients with other types of NSCLC. Differences
among histopathological types were statistically sig-
nificant (p = 0.013). T stage, gender, tumor size,
tumor differentiation, and type of lung resection did
not affect survival. In addition, no significant differ-
ences were observed in the survival rates of patients
with and without lymph vessel or perineural inva-
sion (Table I). The 5-year survival rate was 57% for
patients with invasion of the tumor to the tissue vas-
culature and 75% for patients with no vascular
invasion (p = 0.069).
Staining for EGFR was strong in 19/98, moderate in
32/98, weak in 31/98, and negative in 16/98 tumor
samples (Figure 1). Thus, 51/98 (52%) NSCLC tis-
sues were positive for EGFR expression. The 5-year
survival rates of patients for EGFR positive expres-
sion and EGFR negative expression were 57% and
73%, respectively; this difference was not signifi-
cant (p = 0.13, Figure 2). An analysis of EGFR was
frequent in squamous cell carcinoma (SCC) (61%
for SCC vs. 38% for adenocarcinomas (AC), p =
0.038). EGFR overexpression according to the
pathological stage was 43% in stage I patients, and
65% in stage II (p = 0.04). No statistical association
was found between ERCC1 expression and age, sex,
T stage, vascular invasion, tumor differentiation, or
tumor size. 
Factors that were found to affect the survival rate at
univariate analysis (p < 0.15) (i.e. histopathological
tumor type, blood invasion, tumor stage, and EGFR
expression) were used in a Cox regression analysis
for multivariate analysis of the factors that may
affect the survival rate. The analysis showed that
histopathological tumor type (p = 0.01) and patho-
logical stage (p = 0.03) were both independent
prognostic factors (Table I).
DISCUSSION 
Many patients with NSCLC relapse, and die as a
result, despite the fact that surgical treatment is
potentially curative [17]. Staging helps to predict
the overall survival of a group of patients, but pre-
dicting the prognosis of a specific patient with
NSCLC is not always reliable. Thus, new prognostic
factors are required to determine the subgroup of
patients in the same stage that have relatively poor
prognosis. Inclusion of patients with all stages of
cancer and treated with different modalities in a
study designed to detect prognostic factors may
impede the discovery of effective factors. The effects
of these new factors may remain relatively weak
compared to T, N, and M variables, which are
known to strongly affect survival. We included
patients with early stage tumors without mediastinal
lymph node or distant organ metastasis and without
FIGURE 1: SECTIONS SHOWING TUMOR CELLS STAINED
WITH ANTI-EGFR ANTIBODY IN NSCLC TISSUE SPECIMENS
Definition of abbreviations: EGFR, epidermal growth factor recep-
tor; NSCLC,non-small cell lung cancer.
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onarepre- or post-operative chemo and/or radiotherapy to
minimize the effects of these primary survival mark-
ers. This was expected to uncover the effects of
other potentially useful factors.
In the literature, most of the studies searching for
prognostic factors of NSCLC have been based on
clinical characteristics, histological studies, or
tumor markers, and in recent years on tumor and
cell kinetics, or predictors for response to therapies,
or oncogenes and anti-oncogenes [3,4,18]. Except
for a few, most of the predictors did not really have
significant applications in clinical practice. Benefits
of gefinitib and erlotinib, which were tyrosine
kinase inhibitors from anti-EGFR agents, were
shown to have benefits in advanced NSCLC patients
[19-21]. Due to these studies the importance of
EGFR as a molecular target has increased. The pres-
ence of EGFR mutations has been proposed to be a
positive prognostic factor [22], whereas high-EGFR
copy number and the presence of KRAS mutations
have both been associated to poor prognosis in
resected NSCLC patients [23-25]. EGFR expression
and its “decreased survival” relation with NSCLC
patients has been evaluated for a number of years,
but different studies have yielded controversial
results. 
EGFR is one of the key molecules in lung cancer
initiation and progression, and EGFR is expressed or
overexpressed in a wide variety of solid human
tumors, including NSCLC and breast, gastric, colo -
rectal and bladder cancer [8-10,26,27]. Numerous
studies have suggested that expression of high lev-
els of EGFR is associated with advanced or metasta-
tic disease and a poor prognosis in solid tumors
[26-28]. Unfortunately, the reports about its rela-
tionship with survival have provided inconsistent
results in NSCLC [12-15,29-32].
In the present study, in order to assess the clinical
importance and survival benefit of increased EGFR
expression in early stage NSCLC patients nontreat-
ed (without pre or post operative chemotherapy
and/or radiotherapy), we evaluated the effect of
intratumoral EGFR expression on survival in resect-
ed patients with NSCLC and showed that EGFR
overexpression is not significantly predictive of a
worse prognosis.
Expression of EGFR in NSCLC has been reported
extensively in studies [12,30,31,33,34], with fre-
quencies for EGFR overexpression between 30%
and 89% in NSCLC [12,33-35]. Theoretically, high
EGFR expression in SCC is expected because EGF
promotes the proliferation and differentiation of
epidermal-like tissues. Many studies have shown
that significant differences in EGFR expression have
been reported among histological subtypes, gener-
ally with higher EGFR expression in SCC compared
with other histological types [30,31,34,35]. In our
study, EGFR expression was immunohistochemical-
ly evaluated in 98 formalin-fixed and paraffin-
embedded NSCLC tissues, and 51 (52%) were pos-
itive for EGFR. In agreement with previous findings
[23,24,27], we also found that EGFR expression
was more frequent in SCC than in AC of NSCLC
(63% vs. 38%, p = 0.04). 
Many studies attempting to correlate EGFR overex-
pression with NSCLC patients survival have led to
conflicting results, with some studies reporting no
impact on survival [13-15,34], some a worse sur-
vival [11,12,33]. In these studies both patients with
local disease (stage I-III) and also stage IV patients
were evaluated. Moreover, in these studies EGFR
expression was evaluated by different methods like
IHC, radio-immunoassay (RIA) and enzyme linked
immunoassay (ELISA). Also, the cut off values for
increased EGFR expression differed for each
method. In the review by Nicholson et al. [11],
EGFR overexpression confirmed its prognostic
value in multiple tumor types, but evidence was
weaker in NSCLC. Finally, Nakamura et al. per-
formed a meta-analysis of studies (involving nearly
3,000 patients) evaluating the effect of increased
EGFR expression on the NSCLC patients [36]. In
most of these reported studies EGFR protein expres-
sion was evaluated by IHC methods. And in most of
the studies increased expression of EGFR protein
was not found to be related with poorer prognosis.
In agreement with this meta-analysis, the present
study demonstrated that EGFR expression was not
an independent predictive factor of overall survival
in early stage NSCLC patients. Intervariance
between the results of the studies can be due to use
of different methods in the evaluation of EGFR
expression, acceptance of different threshold levels
for EGFR positivity, and the inclusion of both early
and late disease stages in the patient population.
Despite all these limits of comparability, like most
of the studies our study showed that EGFR can not
be used as a prognostic factor in early stage NSCLC
patients. 
In most of the studies evaluating the EGFR expres-
sion in NSCLC, investigators have reported signifi-
cant correlations between intra tumoral EGFR
expression and more aggressive tumor features,
such as tumor stage [30] or nodal metastases [14].
Increased EGFR expression in metaplastic tissue






















FIGURE 2: SURVIVAL CURVES OF NSCLC PATIENTS WITH
POSITIVE OR NEGATIVE EXPRESSION OF EGFR






























1 [37], and Piyathilake et al. [38] demonstrated a sta-
tistically significant stepwise increase in EGFR
expression from normal bronchial mucosa to
epithelial hyperplasia to cancer, suggesting a pro-
gressive EGFR involvement in lung carcinogenesis.
The present study found a significantly higher
expression of EGFR in stage II compared to stage I.
A tentative hypothesis could be that expression
increases stepwise from precancerous lesions to
more advanced stages of cancer [38]. 
Problems exist with measuring the EGFR levels in
NSCLC. Marked differences in methodology exist
regarding monoclonal antibodies and EGFR detec-
tion techniques. Currently, EGFR analysis has been
performed by immunohistochemistry, immunoassay
(RIA) and enzyme-linked immunosorbent assay
(ELISA). The relationship between these techniques
of EGFR assessment remains uncertain. Because the
immunohistochemical method of detecting EGFR
protein is simple, costs less and can be easily per-
formed in almost any pathology laboratory, the
present findings could be widely applicable in clin-
ical practice. 
Futhermore the advantages of immunohistochem-
istry are the maintenance of the tissue architecture,
the possibility of localizing the antigen and the fact
that it is probably the most applicable and cost-
effective technique for routine use. A highly signifi-
cant correlation between results obtained by ELISA
and immunohistochemistry for the measurement of
EGFR was obtained by Pfeiffer et al. [39] It should
be noted that a previous study has shown that
immunohistochemical staining in NSCLC correlates
with overexpression at the level of total cellular
RNA [40], supporting the use of this technique.
However standard IHC with visual scoring in an
attempt to quantify protein expression has signifi-
cant technical limitations. Besides the subjective
nature of the evaluation, laboratory conditions also
affect the staining (e.g. the nonquantitative chem-
istry of routine immunoperoxidase stains and the
subjective light intensity perception of the human
eye). Moreover, the cut off for the number of posi-
tive cells defining an EGFR-positive tumor is also
often arbitrary and varies according to the investiga-
tors, from a few per cent to 50%. Also immunohis-
tochemical results depend on the primary antibody
used. The dilution of the antibody also differs, lead-
ing to a potential problem because the sensitivity of
the method can depend on the antibody concentra-
tion. Therefore it is difficult to identify an optimal
cut off value for EGFR using immunohistochemistry
in prospective trials. 
Although EGFR expression may not be useful as a
prognostic factor, it has potential clinical implica-
tions. The past few years have seen the rapid devel-
opment of the EGFR inhibitors, and an increasing
body of evidence suggests that selective inhibitors
of EGFR are potential therapeutic agents for the
treatment of NSCLC in adjuvant, metastatic and
chemopreventive settings [41]. In conclusion, the
survival of a patient with NSCLC depends on
numerous factors, and accurately determining the
prognosis of a specific patient is not possible. EGFR,
a major factor that influences tumor formation and
progression, is not a reliable predictor of the sur-
vival rates in resected NSCLC. 
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